Contract research organization Pharmaceutical Product Development Inc (PPD) has moved further into providing central laboratory services with the purchase of a 130,000 sq. ft. laboratory from Merck & Co.
WuXi AppTec is to use ThalesNano’s H-Cube for laboratory-based hydrogenation, which the CRO believes offers advantages in drug discovery over traditional batch processes.
Covance has cut its financial projections for 2008 and 2009 after seeing softening demand for its early-stage services, including toxicology and clinical pharmacology.
Simple preclinical experiments should be able to predict whether immunotherapeutic medicines are safe to advance to preclinical testing in humans and avoid the Northwick Park trial that left six healthy volunteers hospitalised.
US contract research company MPI Research is laying off around 200 employees, but will still end the year with a higher headcount as it takes over two former Pfizer offices, according to local news reports.
Icon's recent $43.2m acquisition of New York-based Prevalere Life Sciences is the latest part of the firm's expansion in the US CRO market. Outsourcing-Pharma spoke with Icon's VP of bioanalytical development, Brian O'Dwyer, and Prevalere...
Applied Cytometry (AC) hopes its VenturiOne v3 software, which is capable of processing 400 files in under 10 seconds, will win over drug developers looking to expedite large-scale laboratory analysis.
Quintiles Transnational has boosted its array of services for companies developing cancer drugs via the purchase of Illinois, US-based firm Targeted Molecular Diagnostics.
The US CRO market is predicted to have a healthy future, with the greatest potential for growth in the preclinical sector, according to a report by Frost & Sullivan.
UK company ProImmune has launched a suite of services to help drugmakers determine at an early stage whether a biologic drug will elicit an immune response in humans.
US company Smithers Group has launched a formulation services company to tap into the emerging trend towards outsourcing of drug development among pharmaceutical companies.
AgilityBio, a division of BioImagene, and Advinus Therapeutics, have teamed up to bolt on imaging services to the latter’s existing preclinical development offering.
Johnson & Johnson has tapped Chinese WuXi PharmaTech for additional R&D services, following the trend towards high-level, strategic collaborations between drugmakers and contract research organisations.
Tepnel Life Sciences has expanded its pharmaceutical services offering by becoming the UK’s first genetic analysis services provider to use Illumina’s next-generation iScan system.
Charles River Laboratories has opened a new preclinical development facility in Shanghai, China which, the firm says, will act as a centre of excellence and help strengthen its position in the global outsourcing market.
San Diego-based biotechnology contract research organisation (CRO) Bio-Quant has expanded its animal diagnostic services offering to cover all nine species used in medical research.
Drug discovery informatics and services provider Tripos International has continued to flourish under the ownership of Vector Capital and is collaborating with AstraZeneca (AZ) to improve drug discovery workflows.
UK-based automation expert, Astech Projects, has been signed up to assist a ‘top 5 pharmaceutical company’ just months after launching its new automation maintenance service.
Indian pharmaceutical companies are making their first forays in the biotechnology arena, helping the market expand from a standing start at the beginning of the decade to reach a value of $2bn in 2006-7, according to a recent report from KPMG.
Ion channel expert ChanTest is expanding its range of ion channel services and cell lines that help identify promising target compounds and those that could cause harmful side effects.
Phylogeny has launched the first microRNA (miRNA) in situ hybridisation detection service to help scientists delve deeper into the mechanisms controlling key biological processes.
UK-based Pharmaceutical Profiles has used an imaging technique known as scintigraphy to quantify the effects of Amylin / Eli Lilly’s latest diabetes drug on the stomach.
Charles River Laboratories has agreed to buy US-based drug discovery imaging expert Molecular Imaging Research, Inc. (MIR) for approximately $12.5m (€8.8m) in cash.
Assay Depot, a new online marketplace which allows bench researchers around the world to choose and buy a broad range of drug discovery services, went live yesterday.
BioReliance has had to significantly expand its Rockville, US, facility and hire new staff in order to accommodate the growing demand for its genetic toxicology (GeneTox) testing services.
Drug discovery informatics and services provider, Tripos International, has agreed to buy Pharsight Corporation, a provider of software and strategic services for clinical drug development.
UK analytical services expert, Quotient Bioscience has received a significant equity investment from TA Associates to help further the firm’s acquisition-led and organic growth strategy.
Caliper Life Sciences has launched two new kinase profiling services as well as new assay kits that aim to provide researchers with a better understanding of their kinase inhibitor drug candidates.
A milestone payment from Bristol-Myers Squibb for the successful advancement of a project into clinical development, along with strong sales by its contract research and manufacturing services unit, prompted Albany Molecular Research Inc (AMRI) to hike...
UK laboratory services firm LGC has brought the first BioMark system into the UK in order to accurately quantify rare gene sequences for its pharmaceutical customers.
Galapagos has bolstered the portfolio of its BioFocus DPI contract services unit by purchasing the structure-based drug discovery business of UK firm Sareum.
AstraZeneca and Singapore’s National Cancer Centre (NCCS) have selected inoperable hepatocellular carcinoma (HCC) as the first target for their new drug collaboration.
Charles River Laboratories saw its operating income advance 16 per cent to $77m in the second quarter on strong demand for its research services division, and also announced a $53m deal to buy a German contract service organisation.
Eli Lilly took a giant leap down the outsourcing road yesterday with the sale of a major R&D facility to contract research organisation Covance and the forging of additional agreement with Quintiles and i3.
US contract research giant Covance saw a strong performance across its divisions in the second quarter that lifted its revenues by 15 per cent to $462m.
The estimated 15 year period, $800m (€509) investment and one in 5,000 chance of successfully developing a new drug is likely to see more and more pharmaceutical firms partner with CROs in a bid to offset risk, according to a report Turner Investment...
India's Jubilant Biosys, a subsidiary of Jubilant Organosys, has scored a major deal with US biotech giant Amgen for the provision of early-stage drug discovery services.
Life science tools and services company MDS Inc has said it will cut about 210 jobs at two of its divisions - its MDS Pharma Services and MDS Analytical Technologies – in a bid to reduce costs by around $20m a year.
Pharmaceutical companies in the developed world have already
shifted substantial manufacturing and clinical trial work to
emerging economies such as China and India, but a new study suggest
they are increasingly counting on these...
MDS Analytical Technologies has followed its acquisition of
Molecular Devices last year by snapping up high content screening
(HCS) experts Blueshift for $15m (€9.45m).
Immtech Pharmaceuticals has become the latest in a string of
western research and development services firms to announce a
partnership with a peer in China in a bid to get a foothold in this
market of vast potential.
Commonwealth Biotechnologies (CBI) has planted its first roots in
Japan, as the world's number two pharmaceutical market continues to
attract foreign firms.
Singapore's Economic Development Board has been taking strides over
the past year to further its biomedical sciences industry and vie
for global attention amidst the other Asia Pacific players,
particularly in the field of translational...
Canada has bought its laboratory legislation in line with other
international standards as the country proposes new legislation
designed to tighten safety and access to human pathogens and
toxins.
India's GVK BIO has secured a new research agreement with drug
giant Wyeth Pharmaceuticals, as more and more pharma firms are
relying on outside partners for drug discovery innovations.
Quotient BioResearch has consolidated its three latest drug
development acquisitions under a united front and the hungry firm
is now on the hunt for further purchases.
